General
Preferred name
SOTAGLIFLOZIN
Synonyms
LP-802034 ()
LX-4211 ()
Sotagliflozin (LX4211) ()
Sar-439954 ()
LX4211 ()
Sar439954 ()
P&D ID
PD016991
CAS
1018899-04-1
Tags
available
drug
Approved by
EMA
FDA
First approval
2019
Drug Status
investigational
approved
Drug indication
Cardiovascular disease
Type-2 diabetes
Type-1 diabetes
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Sotagliflozin is a dual inhibitor of the sodium/glucose cotransporters 1 and 2 (SGLT1/2) . SGLT1 and SGLT2 mediate glucose reabsorption, by the kidney and in the gastrointestinal tract respectively.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
21
Molecular Weight
424.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
3.17
TPSA
79.15
Fraction CSP3
0.43
Chiral centers
5.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Membrane Transporter/Ion Channel
Target
SGLT1
SGLT2
SLC5A1, SLC5A2
SGLT
MOA
sodium/glucose cotransporter inhibitor
Source data
